display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
squamous - mNSCLC - L1 - all population
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC CA184-104
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel IMpower-131 ...
atezolizumab plus carboplatin plus paclitaxel IMpower-131 ...
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-407

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons